Acute Effects of Whole-body Vibration Training in Hypoxia and Normoxia in Multiple Sclerosis Patients

Acute Effects of Whole-body Vibration Training in Hypoxia and Normoxia Condition on Neuromuscular Performance and Mobility in Patients With Multiple Sclerosis

Multiple Sclerosis (ME) is a degenerative, inflammatory and autoimmune demyelinating disease of the central nervous system, characterized by demyelination due to inflammation and degeneration of the myelin sheaths enveloping nerves of the eye, periventricular grey matter, brain, spinal cord and brainstem. The symptoms associated with MS include symptomatic fatigue, muscle weakness, ataxia, mobility and balance problems or cognitive problems. Moderate intensity strength training has been shown to improve strength and mobility in persons with MS. It was suggested that whole-body vibration training (WBVT) is effective to improve muscle strength, such as resistance training, resulting from both neural and structural adaptations. On the other hand, traditional strength training in hypoxia has garnered much attention. This method has shown improvements in isometric strength and increases in muscle size.

Study Overview

• Status: Completed
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Other: Exercise

Detailed Description

• Crossover.
• 13 patients with multiple sclerosis were recruited.
• Patients performed two sessions: whole-body vibration training in normoxia condition and whole-body vibration in hypoxia condition.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Murcia, Spain, 30107
    • Universidad Católica San Antonio

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• mild or moderate disability with clinical mild spastic-ataxic gait disorder.
• stable phase of the disease.

Exclusion Criteria:

• Expanded Disability Status Scale (EDSS) < 6.
• relapsing disease within the preceding 12 months.
• corticosteroid treatment within the last months before study inclusion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Whole-body vibration in normoxia condition; Training session in normoxia condition	Other: Exercise; Whole-body vibration training in hypoxia and normoxia condition
Experimental: Whole-body vibration in hypoxia condition; Training session in hypoxia condition	Other: Exercise; Whole-body vibration training in hypoxia and normoxia condition

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximal Voluntary Isometric Contraction of Knee Extension		Immediately before the training sessions
Maximal Voluntary Isometric Contraction of Knee Extension		Immediately after the training sessions
Rate of Force Development		Immediately before the training sessions
Rate of Force Development		Immediately after the training sessions
Central Activation Ratio		Immediately before the training sessions
Central Activation Ratio		Immediately after the training sessions
Biomechanical study of the walk by video recording	Kinematic analysis of knee and ankle angles during walking	Immediately before the training sessions
Biomechanical study of the walk by video recording	Kinematic analysis of knee and ankle angles during walking	Immediately after the training sessions
Biomechanical study of the walk by video recording	Stride amplitude during walking	Immediately before the training sessions
Biomechanical study of the walk by video recording	Stride amplitude during walking	Immediately after the training sessions
Spasticity	Pendulum test	Immediately before the training sessions
Spasticity	Pendulum test	Immediately after the training sessions

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Perceived Exertion	RPE Scale 6-20	Immediately before the training sessions
Rate of Perceived Exertion	RPE Scale 6-20	Immediately after the training sessions
Walking speed	Test 10 m-walks	Immediately before the training sessions
Walking speed	Test 10 m-walks	Immediately after the training sessions
Static balance	Romberg Test with eyes open and closed. Analysis with force plates	Immediately before the training sessions
Static balance	Romberg Test with eyes open and closed. Analysis with force plates	Immediately after the training sessions
Muscle oxygenation in soleus	MOXY's	Immediately before the training sessions
Muscle oxygenation in soleus	MOXY's	Immediately after the training sessions

Collaborators and Investigators

• Sponsor: Universidad Católica San Antonio de Murcia

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2018
• Primary Completion (Actual): July 30, 2018
• Study Completion (Actual): August 30, 2018

Study Registration Dates

• First Submitted: February 13, 2019
• First Submitted That Met QC Criteria: February 25, 2019
• First Posted (Actual): February 27, 2019

Study Record Updates

• Last Update Posted (Actual): February 27, 2019
• Last Update Submitted That Met QC Criteria: February 25, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Keywords: hypoxia; strength; whole-body vibration; neuromuscular disease
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Signs and Symptoms, Respiratory; Multiple Sclerosis; Sclerosis; Hypoxia
• Other Study ID Numbers: CE061908

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No